Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy March 4, 2026 Jennifer E. Thomas, Anna Dellarole, Robin J. Jacobs
Current literature most strongly supports MDMA and intravenous ketamine as treatments for PTSD. Under professional supervision, these agents may reduce PTSD symptoms and are generally well tolerated. However, findings require cautious interpretation because of limitations including treatment expectancy effects and potential inadequate blinding. Additional randomized controlled trials of other psychedelics, such as psilocybin and lysergic acid diethylamide, are necessary to evaluate their effectiveness for PTSD.